Agenus Announces Shift in Phase 3 Colon-Cancer Strategy and Secures $85 Million Financing
Biotech firm Agenus announced a strategic shift to focus its Phase 3 colon-cancer trial on the ROBBIN study, while discontinuing support for BATTMAN. The company secured an upfront payment of $85 million through a private placement and could receive up to another $255 million if warrants are exercised in full.
Tickers: $AGEN